Engineering therapeutic proteins.
Many early drug candidates derived from biotechnology failed in clinical trials because of their low affinity/specificity, short half-lives or immunogenicity. Protein engineering techniques have been applied to circumvent some of the problems that hindered these earlier trials, resulting in clinical benefits from a range of engineered antibodies and other proteins.
McCafferty
J
J
Cambridge Antibody Technology, Melbourn, Cambridgeshire, UK. john.mccafferty@cambridgeantibody.com
Glover
D R
DR
D000818:Animals; D015195:Drug Design; D006801:Humans; D015202:Protein Engineering; D011506:Proteins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D011506:Proteins